2015年5月3日

O1-A Approval for a Clinical Fellow in the field of Cardiovascular Medicine in 20 Days

On March 26, 2015, we received another O1-A (Individual with Extraordinary Ability or Achievement) Approval for a Clinical Fellow in the field of Cardiovascular Medicine (Approval Notice)

 
 
General Field: Cardiovascular Medicine
Position at the Time of Case Filing: Clinical Fellow
Petitioner: A Teaching Hospital
Country of Origin: India
Service Center: Vermont Service Center (VSC)
State of Residence at the Time of Filing: New York
Approval Notice Date: March 26th, 2015
Processing Time: 20 Days



 
Case Summary:
Similar to our EB1-A cases, O1-A cases require that clients demonstrate that they meet at least three of the regulatory criteria set by the USCIS and that they have achieved sustained national or international acclaim specified in this petition, and that the petitioner seeks to employ the beneficiary to continue his work in the field of endeavor in the United States.
This specific client is a clinical fellow in the field of cardiovascular medicine. His work focuses on medicine for the treatment of cardiovascular diseases. Successful research in our client’s field addresses some of the most advanced issues facing national and international healthcare, including the ability to treat common diseases in the United States. His petitioning organization is a teaching hospital located in Massachusetts. Our client’s research has resulted in at least 24 peer-reviewed scholarly publications appearing in leading journals and 16 presentations at national and international conferences as well as 3 book chapters. His scientific articles have been cited at least 199 times by researchers around the globe. He has also reviewed at least 9 papers submitted to prestigious international journals, and been named an Associate Editor for several journals. His expertise can also be seen in a discussion by a fellow researcher about the impact of our client’s work: “[Client] found a clinically significant reduction in blood pressure for patients given statins. As a direct result of this project, we have better treatments for hypertensive patients. [Client] created a new tool in the physician’s arsenal, and the health of millions of Americans has been improved by this work.
In this case we proved that our client had satisfied the criteria to qualify as an individual of extraordinary ability, had risen to the top of their field of endeavor, had sustained national or international acclaim, and that they sought to enter the United States to continue their outstanding research work in the field of endeavor for a qualified petitioner with the ability to pay.









 
North America Immigration Law Group (Chen Immigration Law Associates) are pleased to announce that we have received a record-breaking number of EB1A/EB1B/NIW approval notices in the first quarter of 2015 – 358 approval notices! We continue to be the leading law firm for employment-based green card application specializing in EB1A, EB1B and EB-2 NIW petitions.
Specifically, in the first quarter of 2015:
January, We received 52 approvals for EB1A, 82 approvals for NIW and 9 approvals for EB1B*;
February, we received 44 approvals for EB1A, 47 approvals for NIW and 6 approvals for EB1B*; and
March, we received 62 approvals for EB1A, 48 approvals for NIW and 8 approvals for EB1B*.
In 2014, we have received 915 EB-1A, EB-1B* and EB-2 NIW approval notices.
Our approval rate in 2014 for all NIW cases is 98.81%. The approval rate for all “Approval or Refund®” NIW cases is 99.75%.
Our approval rate in 2014 for all EB1A cases is 96.20%. The approval rate for all “Approval or Refund®” EB1A cases is 97.32%.
Our approval rate in 2014 for all EB1B* cases is 96.88%. The approval rate for all “Approval or Refund®” EB1B* cases is 97.83%.
The overall approval rate for all NIW, EB1A and EB1B* “Approval or Refund®” cases is 98.65%.

*The number of approval notice for EB1B cases is under-estimated of the total EB1B cases we successfully petitioned because many EB1B employer petitioners did not submit G-28 and we are not the attorney on the record.
*In 2014, one of our EB1B cases (regular service) was denied based on an inaccurate adjudication. The case was approved shortly after we re-filed the petition.
*The approval rate statistics only include cases that were originally filed by our law firm and exclude RFE cases that were taken over in the middle from other law firms or DIY clients.

If you are interested in employment-based green card petitions (EB1/NIW), please send us your CV atlaw@wegreened.com. Our attorneys will provide you with a free evaluation within 24 business hours.
To provide the best immigration service, North America Immigration Law Group (WeGreened.com) only hires attorneys with J.D. degree from top law schools. We specialize in National Interest Waiver (NIW), Aliens of Extraordinary Ability (EB1A) and Outstanding Professors and Researchers (EB1B) petitions.
Approval of each case is the goal of our law firm. Our legal arguments and strategies are formulated based on systematic knowledge and comprehensive database on AAO decisions and RFEs issued by each TSC/NSC immigration officer, resulting in a proven record of low RFE/denial rate and high success rate.
We are one of the leading U.S. immigration law firms providing the most comprehensive services (Letters/PL/RFE) for EB-1/NIW petitions and the only U.S. immigration law firm with money back guarantee (Approval or Refund® Service). We are pleased to have assisted clients from all over the world with nearly a thousand annual approvals and high overall EB1/NIW success rate of 98.5%. For more information, please see our firm’s Success Stories and Approval Notices.

Approval Notices: http://www.wegreened.com/eb1_niw_approvals
Success Stories: http://blog.wegreened.com/
Website: www.wegreened.com
Free evaluation email: law@wegreened.com
Tel: 888.666.0969 (Toll Free)
 

To see more clients’ testimonials and approvals, please refer to:
 

To Learn More About Your Options CLICK HERE



 
Copyright © North America Immigration Law Group – WeGreened.com, All Rights Reserved.